143 results on '"Westerhout, Ellen M."'
Search Results
2. Supplementary Data from Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors
3. Supplementary Table 1 from Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
4. Data from Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors
5. Supplementary Table 2 from Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
6. Supplementary Methods from FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma
7. Data from FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma
8. Supplementary Figure and Table Legends from FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma
9. Supplementary Table S1 from FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma
10. Supplementary Figures S1-S5 from FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma
11. FOXO3A-short is a novel regulator of non-oxidative glucose metabolism associated with human longevity
12. Homo sapiens FOXO3A-short (FOXO3A) mRNA, complete cds.
13. FOXO3A ‐short is a novel regulator of non‐oxidative glucose metabolism associated with human longevity
14. Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate
15. DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma
16. Correction: Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors
17. DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma
18. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth
19. Inactivation of CDK2 Is Synthetically Lethal to MYCN Over-Expressing Cancer Cells
20. Mesenchymal-Type Neuroblastoma Cells Escape ALK Inhibitors
21. DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma
22. An immature subset of neuroblastoma cells synthesizes retinoic acid and depends on this metabolite
23. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
24. RNA interference against viruses: strike and counterstrike
25. Viral immune evasion: a masterpiece of evolution
26. A systematic analysis of the effect of target RNA structure on RNA interference
27. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome
28. Identification of BIRC6 as a novel intervention target for neuroblastoma therapy
29. Abstract 3662: Plasticity of transcriptional and epigenetic cellular states in neuroblastoma is driven by core lineage transcription factors
30. A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma
31. Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway
32. FOXO3A-Short is a Novel Regulator of Non-Oxidative Glucose Metabolism Associated with Human Longevity
33. ALK positively regulates MYCN activity through repression of HBP1 expression
34. HIV-1 latency in actively dividing human T cell lines
35. The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference
36. Abstract 4131: Plasticity of transcriptional and epigenetic cellular states in neuroblastoma is driven by core lineage transcription factors
37. Dendritic Cells Potently Purge Latent HIV-1 in TCR-Activated Cells via the PI3K-Akt-mTOR Pathway: Implications for Shock and Killl Strategies and Reservoir Analysis
38. Abstract 3876: Active enhancers delineate intra-tumor heterogeneity of developmental states in neuroblastoma
39. Neuroblastoma is composed of two super-enhancer-associated differentiation states
40. Abstract 2453: Neuroblastoma is bi-phasic and includes classical neuro-epithelial cells and chemo-resistant mesenchymal cells
41. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
42. Abstract PR08: Neuroblastoma is biphasic and includes classical neuroepithelial cells and chemoresistant mesenchymal cells
43. Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate
44. Abstract 2980: Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
45. Abstract LB-209: Neuroblastoma is biphasic with classical neuro-epithelial cells and chemoresistant mesenchymal cells controlled by PRRX1-NOTCH signaling
46. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
47. Silencing of HIV-1 with RNAi
48. Identification of BIRC6 as a novel intervention target for neuroblastoma therapy
49. FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma
50. Copy number defects of G1‐Cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.